Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 29 tags : Phase 2 save search
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Published: 2021-04-29 (Crawled : 02:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K
|
Health Technology
|
| O: -1.4%
H: 3.77%
C: 2.83%
treatment phase 2 ongoing fibrosis cystic fibrosis
Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting
Published: 2021-04-29 (Crawled : 18:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -1.34%
H: 0.51%
C: -4.75%
phase 2 positive
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2021-04-29 (Crawled : 15:00) - biospace.com/
CARA | $0.69 -5.73% -6.07% 360K
|
Health Technology
|
| O: -43.48%
H: 11.0%
C: -3.47%
phase 2 results dermatitis topline trial atopic dermatitis
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
Published: 2021-04-29 (Crawled : 14:15) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 0.33%
H: 0.77%
C: -4.07%
phase 1 trial phase 3 phase 2
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Published: 2021-04-29 (Crawled : 14:00) - biospace.com/
AERI | $15.25 0.0%
|
Health Technology
|
| O: -0.11%
H: 2.16%
C: -1.36%
dry eye disease treatment phase 2 eye eye disease phase 2b trial enroll
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
Published: 2021-04-29 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.28%
H: 0.87%
C: 0.63%
phase 2 trial macular
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.